Navigation Links
InteKrin Therapeutics to Present at the 27th Annual JP Morgan Healthcare Conference on Tuesday, January 13
Date:1/8/2009

LOS ALTOS, Calif., Jan. 8 /PRNewswire/ -- InteKrin Therapeutics, Inc., will present at the 27th Annual JP Morgan Global Healthcare Conference at 9:00 a.m. Pacific Time on Tuesday, January 13, 2009, to be held at the Westin St. Francis in San Francisco, California. InteKrin Therapeutics' President and CEO Denny Lanfear will present at the conference.

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical stage biopharmaceutical company focused on the development and commercialization of novel drugs for the treatment of diabetes, obesity and metabolic disease. The company's lead program is INT131, a late-stage non-TZD SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator). INT131 is the result of an extensive molecular design effort to address the problematic safety concerns of TZD full PPAR agonists Actos(R) (pioglitazone) and Avandia(R) (rosiglitazone), which while efficacious are associated with weight gain, edema, congestive heart failure and bone fracture. Unlike TZDs, INT131 was specifically selected for its ability to separate powerful PPAR anti-diabetic efficacy from these serious TZD side effects.

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, and is ideally positioned to safely reduce insulin resistance, addressing an important unmet medical need.

InteKrin expects to complete enrollment of its 360 patient, 24-week, placebo-controlled Phase 2b study of INT131 at four doses compared to 45mg Actos in Q1 09 and to have final results later this year.

To learn more about InteKrin, visit http://www.InteKrin.com.


'/>"/>
SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
4. Horizon Therapeutics Announces Senior Management Appointments
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
8. Nile Therapeutics Announces Positive Results from Phase 1b Safety and Pharmacodynamics Study of CD-NP in Patients with Heart Failure
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
10. Intradigm Announces Issuance of Key Patent Related to Enhancing Efficacy and Potency of RNAi Therapeutics
11. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Florida , February 11, 2016 ... PositiveID Corporation ("PositiveID" or "Company") (OTCQB: PSID), a ... announced today that its Thermomedics subsidiary, which markets ... on its growth plan in January 2016, including ... distributors, increasing sequential monthly sales growth, and establishing ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... (PRWEB) , ... February 10, ... ... REGN) today announced that it has joined the Human Vaccines Project, a ... infectious diseases and cancer. , The Human Vaccines Project brings together ...
(Date:2/10/2016)... ... February 10, 2016 , ... HOLLOWAY AMERICA, a ... Engineering (ISPE) Rocky Mountain Chapter 21st Annual Vendor Exhibition on Thursday, February 18, ... 100 tables for its annual event, which will run from 3:00 p.m. - ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/28/2016)... SAN JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: ... financial results for its second quarter ended December 31, 2015. ... the second quarter of fiscal 2016 increased 2 percent compared to ... the second quarter of fiscal 2016 was $35.0 million, or $0.93 ... Non-GAAP net income for the first quarter of fiscal 2016 ...
(Date:1/25/2016)... -- Glencoe Software, the world-leading supplier of image data management ... the data management solution OMERO Plus for the newly ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... Phenotypic analysis measures the characteristics and behavior of cells, ... such as health and disease, the presence or absence ...
Breaking Biology News(10 mins):